Evidence map›Paper›PMID 40305342›Full record

ArticleBiomolecules2025

The Role of Antigen Carbohydrate 125 in Modulating Soluble ST2: Prognostic-Related Effects in Acute Heart Failure.

Arancha Martí-Martínez, Julio Núñez, Herminio López-Escribano, Elena Revuelta-López, Anna Mollar, Marta Peiró, Juan Sanchis, Antoni Bayés-Genís, Arturo Carratala, Òscar Miró and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Arancha Martí-MartínezClinical Biochemistry Department, Valencia Clinical Hospital, 46010 Valencia, Spain.ORCID 0009-0005-3167-0204
Julio NúñezCardiology Department, Valencia Clinical Hospital, Instituto de Investigación Sanitaria (INCLIVA), 46010 Valencia, Spain.ORCID 0000-0003-1672-7119
Herminio López-EscribanoClinical Biochemistry Department, Valencia Clinical Hospital, 46010 Valencia, Spain.
Elena Revuelta-LópezCentro de Investigación Biomédica en Red Enfermedades Cardiovasculares, 28022 Madrid, Spain.ORCID 0000-0001-8962-5936
Anna MollarCardiology Department, Valencia Clinical Hospital, Instituto de Investigación Sanitaria (INCLIVA), 46010 Valencia, Spain.
Marta PeiróCardiology Department, Valencia Clinical Hospital, Instituto de Investigación Sanitaria (INCLIVA), 46010 Valencia, Spain.
Juan SanchisCardiology Department, Valencia Clinical Hospital, Instituto de Investigación Sanitaria (INCLIVA), 46010 Valencia, Spain.ORCID 0000-0003-0797-8709
Antoni Bayés-GenísCentro de Investigación Biomédica en Red Enfermedades Cardiovasculares, 28022 Madrid, Spain.
Arturo CarratalaClinical Biochemistry Department, Valencia Clinical Hospital, 46010 Valencia, Spain.ORCID 0000-0003-4513-7214
Òscar MiróEmergency Department, Hospital Clínic, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), University of Barcelona, 08036 Barcelona, Spain.ORCID 0000-0002-7924-9751
Pere LlorensEmergency Department, General University Hospital of Alicante, 03010 Alicante, Spain.ORCID 0000-0002-9291-7179
Pablo Herrero-PuenteEmergency Department, Asturias Central University Hospital, 33011 Oviedo, Spain.ORCID 0000-0002-5529-5008

Funding

CIBER Cardiovascular 16/11/00420 and 16/11/00403Unidad de Investigacion Clinica y Ensayos Clinicos INCLIVA Health Research Institutem Spanish Clinical Research Network PT13/0002/0031 and PT 17/0017/0003
6 · The paper itself

Abstract

backgroundAcute heart failure (AHF) is a complex syndrome associated with high mortality and hospital readmissions, characterized by volume overload and inflammation. Soluble ST2 (sST2) and antigen carbohydrate 125 (CA125) are emerging biomarkers that reflect these processes and may interact to influence long-term outcomes in AHF patients. This study aims to examine the prognostic relationship between sST2 and CA125 in predicting mortality and heart failure (HF)-related hospitalizations in patients with decompensated heart failure.

methodsIn a cohort of 635 patients with AHF, we investigated whether the prognostic value of sST2 varies according to CA125 levels (≤35 vs. >35 U/mL). The endpoints were: (a) time to all-cause death, and (b) the combination of time to death or new HF admission.

resultsThis study of EAHFE registry data shows that the association between sST2 and long-term adverse outcomes (mortality and HF hospitalizations) in patients with AHF was differentially influenced by CA125 concentrations (

conclusionsThis study highlights the prognostic interaction between sST2 and CA125 in AHF. Elevated sST2 predicts poor outcomes mainly in patients with high CA125 levels (>35 U/mL), suggesting CA125's role in modulating inflammatory activity in HF. Further research is needed.

Indexed as

CA-125 AntigenHeart FailureInterleukin-1 Receptor-Like 1 ProteinAcute DiseaseAgedAged, 80 and overBiomarkersFemaleHospitalizationHumansMaleMembrane ProteinsMiddle AgedPrognosisBiomarkersCA-125 AntigenIL1RL1 protein, humanInterleukin-1 Receptor-Like 1 ProteinMembrane ProteinsMUC16 protein, humanacute heart failureCA125inflammatory modulatorsST2

Identifiers

PMID40305342
PMCPMC12024938

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.